pijn aan beschadigde organen visceral pain
Conditions
Interventions
Active substance: LY2878735
Activity: Combined serotonin and noradrenaline transporter inhibitor
Indication: Visceral pain syndromes
Strength: 5 mg, 20 mg and 70 mg
Dosage form: capsules
Treatments
Sponsors
Eli Lilly
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy male, age between 18 and 65 years, BMI between 19 and 32.5 kg/m2, non-smoker or moderate smoker, at screening state of health must satisfy the entry requirements. ;Only part B: Non-exposure to any radiation for diagnostic reasons during work or during participation in a medical trial in the past year, non claustrophobic.
Exclusion criteria
Exclusion criteria: D5a: Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacodynamics: plasma DHPG and NE concentrations, NE/5-HT uptake inhibition, occupancy of transporter sites Pharmacokinetics: plasma concentrations, pharmacokinetic parameters Safety: adverse events, vital signs, ECG-parameters, laboratory parameters, physical examination | — |
Secondary
| Measure | Time frame |
|---|---|
| n.a. | — |
Countries
Netherlands
Outcome results
None listed